NCT01650350 2022-03-04
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
Brown University
Phase 2 Terminated
Clinical Trials
3 trialsNCT02137252 2021-11-16
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00379197 2017-12-28
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated